Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,163Revenue $M0Net Margin (%)0Z-Score
Enterprise Value $M1,157EPS $0Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %ROA % (ttm)0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M6.9ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with XBI

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

XBI is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


XBI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Robson, Philip SpencerDirector or Senior Officer of Insider or Subsidiar 2014-12-19Buy5,000$0.8123398.77view
GOODALL, ROBERTDirector, Senior Officer 2014-12-18Buy4,800$11.151607.09view
Worrall, LawrenceDirector 2014-12-18Sell5,000$122.9554.81view
DeMare, NickDirector 2014-12-18Buy90,000$0.011903300view
Mandatum Life Insurance Compan10% Security Holder 2014-12-18Sell16,942$0.4146324.39view
Hannasch, Brian PatrickDirector or Senior Officer of Insider or Subsidiar 2014-12-18Sell87,583$45.68316.68view
MacPhail, Keith A.J.Director, Senior Officer 2014-12-18Buy50,000$50000-99.62view
Leshchyshen, BobSenior Officer 2014-12-18Buy9,500$0.2673107.69view
Di Gennaro, EnzioSenior Officer 2014-12-18Buy200$12.951369.81view
Felderhof, G. WilliamDirector 2014-12-18Buy3,000$0.15126793.33view

Press Releases about XBI :

    Quarterly/Annual Reports about XBI:

      News about XBI:

      Articles On GuruFocus.com
      Are Earnings Important? These Days, Revenues Count for More! Mar 17 2014 

      More From Other Websites
      Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Dec 17 2014
      Viekirax/Exviera vs. Harvoni: Clash of the Hep C Drugs 2015 Dec 16 2014
      Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Dec 12 2014
      Best Biotech ETFs Gets a Lift From Merck’s Cubist Buy Dec 08 2014
      Best Biotech ETF Gets a Lift From Merck’s Cubist Buy Dec 08 2014
      Merck Bid For Cubist Pharma Adds Fuel to Year's Best Biotech ETF Dec 08 2014
      Health Care ETFs Take Over Market Leadership Role Dec 05 2014
      It Could be a Big December for Biotech ETFs Dec 04 2014
      Biogen shows its hand Dec 02 2014
      Zacks Investment Ideas feature highlights: Robo-Stox ETF, First Trust Nasdaq Clean Edge Green Energy... Nov 24 2014
      Invest in Booming Technologies with These 3 ETFs Nov 21 2014
      [video]Future Tech: Berkeley Biolabs CEO on Biotech Investments Not to Miss Nov 15 2014
      The Thorns, Roses, All Time Highs, and ETF All Time Highs... Nov 05 2014
      Biotech Jargon Explained: Special Protocol Assessment Nov 05 2014
      [video]Vote Cannabis? Marijuana Gains Political Traction on the Ballot Nov 04 2014
      Biotech ETF IBB: Cup-&-Handle Breakout Oct 23 2014
      Best And Worst ETFs Of The Week Amid Market Rebound Oct 17 2014
      [video] Pisani's market open: Oversold bounces Oct 14 2014
      SPDR® S&P Biotech ETF Receives Settlement Payment Oct 13 2014
      The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, First... Oct 03 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK